-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Stoke Therapeutics, Lowers Price Target to $58

Benzinga·08/04/2026 12:18:05
语音播报
Canaccord Genuity analyst Sumant Kulkarni maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and lowers the price target from $60 to $58.